{"schema_version":"secwatch.filing_event.v1","accession":"0001999480-24-000025","form_type":"8-K","ticker":"ANRO","cik":"0001999480","company_name":"Alto Neuroscience, Inc.","filed_at":"2024-07-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:15.334890+00:00","generated_at":"2026-05-31T15:48:37.850063+00:00","sec_items":["1.01","2.03","3.02","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Alto Neuroscience secures up to $11.7M convertible loan from Wellcome for ALTO-100 Phase 2b trial","bullets":["Up to $11.663M convertible loan from Wellcome Trust; $2M funded immediately, remainder upon milestones.","Interest accrues at SONIA+2%; convertible into common stock at 20% discount to 30-day VWAP after 2nd anniversary.","Conversion shares capped at 5,363,326 (19.9% of outstanding stock).","Proceeds used exclusively to fund ALTO-100 Phase 2b clinical trial in bipolar depression."],"urls":{"canonical":"https://secwatch.observer/filing/0001999480-24-000025","json":"https://secwatch.observer/filing/0001999480-24-000025.json","markdown":"https://secwatch.observer/filing/0001999480-24-000025.md","text":"https://secwatch.observer/filing/0001999480-24-000025.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1999480/000199948024000025/0001999480-24-000025-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1999480/000199948024000025/alto-20240724.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T15:48:37.850063+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}